Organisation paid for research Program year 2020 Source: CMS Open Payments

Copernicus Group Incorporated Dba Copernicus Group

Neither a doctor nor a teaching hospital

Research payments

$5,037,893

14,417 payments

Through program year 2020, Copernicus Group Incorporated Dba Copernicus Group is reported as receiving $5,037,893 in research payments, across 14,417 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$3,796,272	11,523
2019	Research	$1,241,621	2,894

Breakdown

Who paid Research payments · program years 2019–2020

Allergan Inc. $5,037,893 14,417 payments

Studies the money was for Research payments · program years 2019–2020

12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $685,996 2,083 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $506,680 1,002 payments
A 46-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Longterm Study With A 6-Week Randomized-Withdrawal Period to Evaluate the Safety and $474,192 1,345 payments
A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $394,357 802 payments
Chronic Idiopathic Constipation (Cic),Irritable Bowel Syndrome With Constipation (Ibs-C) $348,894 1,394 payments
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $293,524 1,232 payments
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $255,991 974 payments
A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $236,207 606 payments
A 52-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active- Controlled, Operationally Seamless Phase 2B/3, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohns Disease $219,372 947 payments
Lvm-MD-14 (Prea/Pmr/Phase 3/Double-Blind) $167,278 436 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.